Key result
CHIRP3M-1 score outperforms CHA2DS2-VASc in distinguishing cardioembolic from large artery stroke.
Why the study?
There was no existing prediction system to distinguish the risk of cardioembolic stroke from large artery stroke.
Does the CHIRP 3 M -1 score improve discrimination of cardioembolic stroke from large artery stroke compared to existing risk scores in patients with stroke?
Does the CHIRP 3 M -1 score improve discrimination of cardioembolic stroke from large artery stroke compared to existing risk scores in patients with stroke?
The novel CHIRP 3 M -1 score outperforms the CHA2DS2-VASc score in discriminating cardioembolic stroke from large artery stroke, potentially aiding in targeted stroke mitigation strategies.
Answers are grounded in this paper and cite their sources.
May aid observational stroke subtype classification; leaves open prospective validation before clinical adoption.
Introduction: There is no existing prediction system to distinguish risk of cardioembolic stroke (CES) from large artery stroke (LAS). CHIRP 3 M -1 score is a novel surrogate for reduced left atrial appendage (LAA) emptying velocity. It assigns points for coronary artery disease (1 point), heart failure (1 point), left atrial volume index ≥ 42 mL/m 2 (1 point), rhythm atrial fibrillation (AF, 1 point), history of paroxysmal AF (2 points), persistent AF (3 points), longstanding/permanent AF (4 points), and subtracts 1 point for more than moderate mitral regurgitation. We evaluated the performance of the CHIRP 3 M -1 score as a marker of CES risk. Methods: We conducted a retrospective case-control study using The University of Kansas Medical Center stroke registry to identify patients with neurologist-classified CES or LAS admitted in calendar year 2021. Data collection was supplemented through medial chart review. Cases with CES were compared to controls with LAS. Differences between the CHIRP 3 M -1 , CHIRP 3 , CHA 2 DS 2 -VASc, CHADS 2 , R 2 CHADS 2 and ATRIA scores were examined using Mann-Whitney U tests. Discriminative performance of these scores was compared using area under the receiver operating characteristic curves (AUCs) curves. Results: Among the 341 patients (age 70.2 ± 12.3 years, 153 [44.9%] females) included for analysis, 189 (55.4%) had CES. The mean clinical stroke risk scores for CES vs. LAS as shown in Table 1 and Figure 1 were as follows: CHIRP 3 M -1 (3.4 ± 3.6 vs. 0.9 ± 1.4, p < 0.0001), CHA 2 DS 2 -VASc (3.6 ± 1.5 vs. 3.1 ± 1.6, p = 0.0089) and R 2 CHADS 2 (2.6 ± 1.4 vs. 2.3 ± 1.5, p = 0.0667). The CHIRP 3 M -1 score demonstrated superior discrimination (AUC 0.725) compared to the CHA 2 DS 2 -VASc score (AUC 0.581) in differentiating CES from LAS ( Figure 2 ). A CHIRP 3 M -1 score of ≥ 2 points had a sensitivity of 55.6% and specificity of 78.5% in distinguishing CES from LAS. Conclusions: The CHIRP 3 M -1 score is superior to existing clinical stroke risk models like CHA 2 DS 2 -VASc score in discriminating CES from LAS. Therefore, CHIRP 3 M -1 may be better suited to identify patients for CES mitigation using oral anticoagulation or LAA occlusion.
No takes yet. Share an insight, caveat, or question.
Franken et al. (2026) studied this question. The CHIRP 3 M -1 score demonstrated superior discrimination (AUC 0.725) compared to CHA 2 DS 2 -VASc (AUC 0.581) for distinguishing cardioembolic from large artery stroke.
Synapse has enriched 10 related papers. Consider them for comparative context: